The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention

NCT03331484 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation
Acute Coronary Syndrome

Interventions

DRUG: Ticagrelor
DRUG: Rivaroxaban

Sponsor

Ottawa Heart Institute Research Corporation